Table 3 Incidence rates (IRs) of drug prescription before and after following a Diagnostic Therapeutic Educational Pathway (DTEP), % differences between IRs and incidence rate ratios (IRRs) of after-to-before DTEP IRs, according to children’s age
Drug | Age (years) | Before DTEP | After DTEP | |||||
|---|---|---|---|---|---|---|---|---|
No. | Rate per 1000 (95% CI) | No. | Rate per 1000 (95% CI) | % difference after-before DTEP rates | IRR (95% CI)a | p-value | ||
Inhaled short-acting beta-2 agonist (SABA) | ||||||||
0–2 | 1459 | 1822.5 (1730.2–1918.5) | 2157 | 2029.0 (1944.3–2116.5) | + 11.3 | 1.11 (1.04–1.19) | p = 0.0015 | |
3–5 | 1061 | 1754.0 (1650.0–1862.8) | 2259 | 1748.5 (1677.1–1822.1) | −0.3 | 1.00 (0.93–1.07) | NS | |
Inhaled corticosteroids | ||||||||
0–2 | 1946 | 2430.8 (2324.0–2541.3) | 2757 | 2593.4 (2497.5–2692.0) | + 6.7 | 1.07 (1.01–1.06) | p = 0.0286 | |
3–5 | 1284 | 2122.7 (2008.1–2242.0) | 2734 | 2116.2 (2037.6–2197.0) | −0.3 | 1.00 (0.93–1.07) | NS | |
LABA plus corticosteroids | ||||||||
0–2 | 242 | 302.3 (265.4–342.9) | 244 | 229.5 (201.6–260.2) | −24.1 | 0.76 (0.63–0.91) | p = 0.0025 | |
3–5 | 213 | 352.1 (306.4–402.7) | 325 | 251.6 (225.0–280.5) | −28.6 | 0.71 (0.60–0.85) | p = 0.0002 | |
Leukotriene receptor antagonists | ||||||||
0–2 | 600 | 749.5 (690.7–811.9) | 1621 | 1524.8 (1451.5–1600.9) | + 103.5 | 2.03 (1.85–2.24) | p < 0.0001 | |
3–5 | 497 | 821.6 (751.0–897.1) | 991 | 765.1 (720.0–816.3) | −6.6 | 0.93 (0.84–1.04) | NS | |
Systemic steroids | ||||||||
0–2 | 710 | 886.9 (822.9–954.6) | 905 | 851.3 (796.7–908.6) | −4.0 | 0.96 (0.87–1.06) | NS | |
3–5 | 443 | 732.3 (665.7–803.8) | 592 | 458.2 (422.1–496.7) | −37.4 | 0.63 (0.55–0.71) | p < 0.0001 | |
Antibiotics | ||||||||
0–2 | 5575 | 6964.0 (6782.4–7149.2) | 5100 | 4797.4 (4666.6–4930.9) | −31.1 | 0.69 (0.66–0.72) | p < 0.0001 | |
3–5 | 3262 | 5392.6 (5209.1–5580.9) | 3723 | 2881.7 (2789.4–2975.8) | −46.6 | 0.53 (0.51–0.56) | p < 0.0001 | |